Home » Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients With Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients With Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, Tuesday announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May